Asterias Biotherapeutics (AST) Tops Q2 EPS by 7c

August 15, 2016 4:59 PM EDT

Find out which companies are about to raise their dividend well before the news hits the Street with's Dividend Insider Elite. Sign-up for a FREE trial here.

Asterias Biotherapeutics (NYSE: AST) reported Q2 EPS of ($0.12), $0.07 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $1.53 million versus the consensus estimate of $1.14 million.

For earnings history and earnings-related data on Asterias Biotherapeutics (AST) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories


Related Entities


Add Your Comment